Marker Therapeutics, Inc. (MRKR) Q3 2024 Earnings

MRKR·Reported November 14, 2024·Before market open

Marker Therapeutics, Inc. reported Q3 2024 revenue of $1.9M, beat analyst consensus of $1.0M by $926.0K. Diluted EPS came in at $-0.26, beat the $-0.39 consensus by $0.13.

Revenue

$1.9Mbeat by $926.0K

Consensus: $1.0M

Diluted EPS

$-0.26beat by $0.13

Consensus: $-0.39

SEC Filings

Earnings release8-K not filed yet

Quarterly report10-Q · 0001410578-24-001978

Financial Snapshot

Trailing eight quarters through Q3 2024

View all metrics

Revenue

Net Income

Operating Cash Flow

EPS (Diluted)

Q3 2024 Earnings FAQ

Common questions about Marker Therapeutics, Inc.'s Q3 2024 earnings report.

Marker Therapeutics, Inc. (MRKR) reported Q3 2024 earnings on November 14, 2024 before market open.

Marker Therapeutics, Inc. reported revenue of $1.9M and diluted EPS of $-0.26 for Q3 2024.

Revenue beat the consensus estimate of $1.0M by $926.0K. EPS beat the consensus estimate of $-0.39 by $0.13.

You can read the 10-Q periodic report (0001410578-24-001978) directly on SEC EDGAR. The filing index links above go to sec.gov.